16 November 2017 - - US-based wearable medical devices and diagnostic software developer Cardiac Insight, Inc has secured its first cardiology customers for its wearable ECG sensor device, Cardea SOLO, in Texas and several other states, the company said.

According to Cardiac Insight, early physician and patient experiences with Cardea SOLO are confirming the FDA-cleared cardiac device, designed to streamline arrhythmia detection in patients, is providing a higher standard of ambulatory cardiac care and efficiencies in cardiac practices.

Cardiac Insight said that Cardea SOLO's compact, cable-free ECG device records every heart beat, yet offers longer, comfortable and nonintrusive diagnostic wear time that improves a patient's experience and compliance, especially when compared to a traditional 48-hour ECG monitor.

Its standalone plug-and-play ECG arrhythmia analysis and reporting system seamlessly integrates into a cardiology or other medical clinic's existing operational infrastructure, keeping patient data secure and available immediately for review.

Cardea SOLO is small, lightweight (about the weight of three quarters), water-resistant and single-use disposable.

In September, Cardiac Insight announced another infusion of investment into its active C-1 funding round and development of a Scientific advisory board.

The physicians, nurses and medical assistants of Cardiology Partners have been providing cardiac care for patients in the Mansfield/Arlington, Texas area since 1979.

As the largest cardiology practice in Mansfield, Cardiology Partners offers patient care with a range of in-office treatment options and privileges at all major hospitals in the Mansfield/Arlington area.

Cardiac Insight is a US developer of advanced body-worn digital health care information devices for cardiology, respiratory and other complex disease states.

The company was founded in 2008 and is based in Kirkland, Washington.